TABLE 2.
Omalizumab in chemotherapy desensitisation—current data
| Author (Ref.) | Patients | Drug involved | Omalizumab dose | Interval between omalizumab doses (days) | Interval between omalizumab and CHT (days) | Number of omalizumab doses | Number of desensitisation protocols | Tolerance |
|---|---|---|---|---|---|---|---|---|
| Cahill, 2012 34 | 1 | Oxaliplatin | 150 mg | 14 | UNK | 6 | 5 | Mild reactions |
| Ojaimi, 2014 35 | 1 | Carboplatin | 300 mg | 14 | 1 | 9 | 5 | Yes |
| Saura, 2016 36 | 3 | Carboplatin | UNK | UNK | UNK | UNK | 15 | Yes |
| Garcia, 2016 37 | 1 | Carboplatin | UNK | UNK | UNK | UNK | UNK | Mild reaction |
| Hong, 2018 38 | 5 | CHT (platins, taxanes) or monoclonal antibodies | 300 mg | 28 | UNK | 3 | 3 | Mild reactions |
| Stein, 2018 39 | 9 | Oxaliplatin | 300 mg | 14 | 7 | Median = 5 (1–10) | UK | Yes |
| Prieto‐Garcia, 2019 40 | 1 | Oxaliplatin | 300 mg | 15 | 7 | 13 | 13 | Yes |
| De Las Vaceillas Sánchez, 2019 41 | 1 | Oxaliplatin | 600/300 mg | 14 | 1 | 6 | 5 | Yes |
| Cuevas, 2019 42 | 1 | Oxaliplatin | 300 mg | UNK | 6 | 1 | 1 | Anaphylaxis |
| Sanchez‐Morillas, 2020 43 | 2 | Carboplatin | 300/150 mg | 7/14 a | 1 | 9 | 6 | Yes |
| Carboplatin | 300/150 mg | 7/14 a | 1 | 6 | 4 | Mild reaction | ||
| Oude Elberink, 2020 44 | 1 | Carboplatin | 300 mg | 14 | 11 b | 9 | 9 | Yes |
| Penella, 2020 45 | 1 | Oxaliplatin | 300 mg | 14 | 19/14 c | 5 | 5 | Yes |
Abbreviations: CHT, chemotherapy; RDD, rapid drug desensitisation; UNK, unknown.
a
7 days between 300 and 150 mg of Oma; 14 days between the next 150 mg doses.
b
Before first desensitisation.
c
19 days between the first dose of Oma and CHT‐RDD, then 14 days.